Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. (Q46252246)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Rury Holman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Irene M. Stratton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

A Farmer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

L Tucker

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

H A W Neil

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

50-59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19002433%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-008-1179-5

16 January 2020

exact match

0 references

cites work

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-008-1179-5

Does fish oil lower blood pressure? A meta-analysis of controlled trials

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-008-1179-5

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

21 January 2018

1 reference

12 December 2020

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

1 reference

12 December 2020

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

1 reference

12 December 2020

Standards of medical care in diabetes--2008.

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Omega 3 fatty acids for prevention and treatment of cardiovascular disease

1 reference

12 December 2020

n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol.

1 reference

12 December 2020

Omega 3 fatty acids and cardiovascular disease--fishing for a natural treatment

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

12 December 2020

Triglycerides and the Risk of Coronary Heart Disease

1 reference

12 December 2020

Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial

1 reference

12 December 2020

Beyond lipid lowering: the anti-hypertensive role of statins

1 reference

12 December 2020

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

12 December 2020

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

1 reference

12 December 2020

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

12 December 2020

UK Prospective Diabetes Study (UKPDS). XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects

1 reference

12 December 2020

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

12 December 2020

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.

1 reference

12 December 2020

Do Statins Reduce Blood Pressure?

1 reference

12 December 2020

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

1 reference

12 December 2020

Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications

1 reference

12 December 2020

Fibrates in combination with statins in the management of dyslipidemia

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.

1 reference

12 December 2020

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

12 December 2020

Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

1 reference

12 December 2020

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes

1 reference

12 December 2020

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020